Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.
暂无分享,去创建一个
F. Cavalli | B. Coiffier | E. Pedrinis | G. Pruneri | G. Martinelli | E. Zucca | A. Ferreri | M. Ponzoni | F. Peccatori | S. Dell'oro | P. Dietrich | C. Thieblemont | A. Gianni | A. Conconi | L. Devizzi | V. Filipazzi
[1] Daniel Campbell. Nonparametric Statistics , 2022, Encyclopedia of Autism Spectrum Disorders.
[2] A. Nicholson,et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. , 2003, Blood.
[3] Peter Marynen,et al. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. , 2003, Blood.
[4] A. López-Guillermo,et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. , 2003, Blood.
[5] G. Ott,et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. , 2003, Blood.
[6] J. Hainsworth,et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Dimopoulos,et al. Treatment of Waldenström's macroglobulinemia with rituximab. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] F. Cavalli,et al. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. , 2002, Blood.
[9] A. Ng,et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. , 2002, International journal of radiation oncology, biology, physics.
[10] M. Du,et al. Gastric MALT lymphoma: from aetiology to treatment. , 2002, The Lancet. Oncology.
[11] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[12] E. Erba,et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone , 2001, British journal of haematology.
[13] A. Bezjak,et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. , 2001, International journal of radiation oncology, biology, physics.
[14] S. Chimenti,et al. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. , 2001, Acta dermato-venereologica.
[15] M. Stolte,et al. Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] E. Vitetta,et al. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. , 2001, Blood.
[17] J. Vose,et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Ming-Qing Du,et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy , 2001, The Lancet.
[19] G. Salles,et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. , 2000, Blood.
[20] M. Czuczman,et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] F. Gherlinzoni,et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] V. Diehl,et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.
[24] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Yahalom,et al. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] F. Cavalli,et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. , 1997, Leukemia & lymphoma.
[27] G. Salles,et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] P. Gaulard,et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] D. G. Altman,et al. Review of survival analyses published in cancer journals. , 1995, British Journal of Cancer.
[30] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[31] K. Lennert,et al. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. , 1991, Gastroenterology.
[32] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[33] W. W. Daniel. Applied Nonparametric Statistics , 1978 .
[34] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[35] Dong Suk Kim,et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue–type of the orbit and ocular adnexa , 2004, Annals of Hematology.
[36] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[37] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[38] B. Coiffier,et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] F. Cavalli,et al. The gastric marginal zone B-cell lymphoma of MALT type. , 2000, Blood.
[40] L. Gordon,et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.